B Cell Nhl clinical trials

Explore recruiting b cell nhl clinical trials.

Recruiting b cell nhl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Nhl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma

France, Netherlands, Hungary, Czechia, Germany, Spain +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

IKS03 in Advanced B cell NHL

Spain, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 (19CP02) in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma

Netherlands, Belgium, Finland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) )

Germany, Spain, Denmark, Italy, Sweden, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II Trial to Determine Persistence, Safety and Clinical Activity of Allogeneic CIK Cells Transduced with a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) in Adult and Pediatric Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

B Cell Nhl trials by city

B Cell Nhl in Toronto B Cell Nhl in Vancouver B Cell Nhl in Montreal B Cell Nhl in Calgary B Cell Nhl in Edmonton B Cell Nhl in Ottawa B Cell Nhl in Winnipeg B Cell Nhl in Quebec City B Cell Nhl in Hamilton B Cell Nhl in Kitchener B Cell Nhl in London B Cell Nhl in Halifax B Cell Nhl in New York B Cell Nhl in Los Angeles B Cell Nhl in Chicago B Cell Nhl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease